Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials . J of Skin [Internet]. 2022 Nov. 16 [cited 2025 May 14];6(6):s64. Available from: https://skin.dermsquared.com/skin/article/view/1819